Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Drug-Drug Interaction Study to Assess the Effect of Orforglipron on the Pharmacokinetics of Digoxin, Simvastatin, Rosuvastatin, Acetaminophen, and Midazolam in Healthy Overweight and Obese Participants

NCT06186622 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT06186622
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06186622 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Drug-Drug Interaction Study to Assess the Effect of Orforglipron on the Pharmacokinetics of Digoxin, Simvastatin, Rosuvastatin, Acetaminophen, and Midazolam in Healthy Overweight and Obese Participants
Lead sponsor
Eli Lilly and Company
Phase
Phase 1
Overall status
Completed
Start date
January 2, 2024
Completion date
July 10, 2024
Enrollment
50 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

healthy, obese, overweight